Content about South San Francisco, California

April 30, 2013
FDA approves Genentech arthritis drug for rare disorder in children

The Food and Drug Administration has approved a drug made by Genentech for a rare form of arthritis in children, the company said Tuesday.

SOUTH SAN FRANCISCO, Calif. — The Food and Drug Administration has approved a drug made by Genentech for a rare form of arthritis in children, the company said Tuesday.

Genentech, a subsidiary of Swiss drug maker Roche, announced the approval of Actemra (tocilizumab) for polyarticular juvenile idiopathic arthritis in children ages 2 years and older, either alone or combined with the generic drug methotrexate.

February 22, 2013
FDA approves Genentech breast cancer drug

The Food and Drug Administration has approved a new treatment for late-stage breast cancer, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for late-stage breast cancer, the agency said Friday.

The FDA announced the approval of Genentech's Kadcyla (ado-trastuzumab emtansine) for HER2-positive breast cancer that has spread to other parts of the body. HER2 is a protein involved in the growth of normal cells but found in increased amounts in some kinds of cancer cells, which contributes to cancer cell growth and survival. Genentech is the U.S. subsidiary of Swiss drug maker Roche.

October 12, 2012
FDA approves new use for Genentech arthritis drug

The Food and Drug Administration has approved a new use for a drug made by Roche division Genentech.

SOUTH SAN FRANCISCO, Calif. — The Food and Drug Administration has approved a new use for a drug made by Roche division Genentech.

The drug maker said Friday that the FDA had approved Actemra (tocilizumab) for adults with moderately to severely active rheumatoid arthritis who have not responded adequately to one or more disease-modifying antirheumatic drugs. The drug was already approved for systemic juvenile idiopathic arthritis.

July 27, 2012
FDA panel recommends new approval for Genentech eye drug

A panel of Food and Drug Administration experts is recommending the approval of a drug made by Genentech for diabetic macular edema, the company said.

SILVER SPRING, Md. — A panel of Food and Drug Administration experts is recommending the approval of a drug made by Genentech for diabetic macular edema, the company said.

April 30, 2012
Reports: Dying woman's plea prompts early release of cancer drug

An online plea for help from a mother dying of breast cancer prompted the manufacturer of an experimental drug to release it early, according to published reports.

NEW YORK — An online plea for help from a mother dying of breast cancer prompted the manufacturer of an experimental drug to release it early, according to published reports.

In an article posted on its website, CNN told the story of 46-year-old Darlene Gant, a woman with stage-four breast cancer, as she wrote letters to be given to her 11-year-old son on his upcoming birthday, and at future events, such as his high school and college graduations and marriage.

January 30, 2012
FDA approves Genentech skin cancer drug

The FDA announced the approval of Genentech's Erivedge (vismodegib) for adults with basal cell carcinoma who are not surgery or radiation therapy candidates and whose disease is locally advanced or has spread to other parts of the body.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for treating the most common type of skin cancer, the agency said Monday.

The FDA announced the approval of Genentech's Erivedge (vismodegib) for adults with basal cell carcinoma who are not surgery or radiation therapy candidates and whose disease is locally advanced or has spread to other parts of the body.

September 12, 2011
Genentech files for approval of skin cancer drug

Genentech has applied for Food and Drug Administration approval of a drug for treating skin cancer, the drug maker said Monday.

SOUTH SAN FRANCISCO, Calif. — Genentech has applied for Food and Drug Administration approval of a drug for treating skin cancer, the drug maker said Monday.

Genentech, the U.S. division of Swiss drug maker Roche, submitted a new drug application to the FDA for vismodegib for the treatment of basal cell carcinoma. BCC generally is curable through surgery, but if it advances, can cause disfigurement and debilitating effects and, in the long term, can be life-threatening.

April 18, 2011
FDA approves Actemra as arthritis treatment for children

The Food and Drug Administration has approved a drug made by Genentech for treating a rare and severe form of arthritis that affects children, Genentech said.

SOUTH SAN FRANCISCO, Calif. — The Food and Drug Administration has approved a drug made by Genentech for treating a rare and severe form of arthritis that affects children, Genentech said.

The biotech company, the U.S. division of Swiss drug maker Roche, announced the FDA approval of Actemra (tocilizumab) for active systemic juvenile idiopathic arthritis. SJIA has the worst long-term prognosis of all varieties of childhood arthritis.

January 6, 2011
Genentech granted supplemental approval for Actemra

The Food and Drug Administration has expanded the approved usage of a drug made by Genentech, part of Swiss drug maker Roche.

SOUTH SAN FRANCISCO, Calif. — The Food and Drug Administration has expanded the approved usage of a drug made by Genentech, part of Swiss drug maker Roche.

The FDA approved Actemra (tocilizumab) for the inhibition and slowing of structural joint damage, improvement of physical function and achievement of clinical response in patients with moderate to severe rheumatoid arthritis. The drug originally was approved as a treatment for RA last year.

December 15, 2010
Former Genentech executive named P&G board member

Procter & Gamble on Tuesday afternoon named a healthcare veteran to its board. Susan Desmond-Hellmann, 53, chancellor of the University of California, San Francisco was named to the board, effective Dec. 13.

CINCINNATI — Procter & Gamble on Tuesday afternoon named a healthcare veteran to its board. Susan Desmond-Hellmann, 53, chancellor of the University of California, San Francisco, was named to the board, effective Dec. 13.

September 19, 2010
Genentech amends approval application for expanded use of Avastin

Biotech company Genentech has amended its application to the Food and Drug Administration seeking an...

SOUTH SAN FRANCISCO, Calif. Biotech company Genentech has amended its application to the Food and Drug Administration seeking an additional approval for one of its drugs, which the FDA has deemed a “major amendment,” Genentech said Monday.

 

May 9, 2010
Genentech, Evotec to collaborate on drug development

U.S. biotechnology company Genentech and German drug maker Evotec hope to develop drugs using Evotec’s...